New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors

European Journal of Medicinal Chemistry

Volumn 80, Issue , 2014, Pages 101-111

  Famiglini, Valeria ^a   La Regina, Giuseppe ^a   Coluccia, Antonio ^a   Pelliccia, Sveva ^a   Brancale, Andrea ^b   Maga, Giovanni ^c   Crespan, Emmanuele ^c   Badia, Roger ^d   Clotet, Bonaventura ^d   Esté, José A ^d   Cirilli, Roberto ^e   Novellino, Ettore ^f   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CNR   (Italy)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

AIDS; HIV 1; Indolylarylsulfone; Nonnucleoside inhibitor; Reverse transcriptase

Indexed keywords

DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; INDOLYLARYLSULFONE DERIVATIVE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; UNCLASSIFIED DRUG; INDOLE; INDOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ENANTIOMER; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; MUTANT; NONHUMAN; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HUMAN; IC50; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CELL LINE; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 84899103627     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.04.027     Document Type: Article

References (27)

1. R. Lafemina Antiviral Research: Strategies in Antiviral Drug Discovery (Chapters 2-7) 2009 AMS Press Washington
2. H.W. Virgin, and B.D. Walker Immunology and the elusive AIDS vaccine Nature 464 2011 224 231
3. Antiretroviral Drugs Used in the Treatment of HIV Infection, FDA (last update Dec. 18th, 2012).
4. J.A. Este, and T. Cihlar Current status and challenges of antiretroviral research and therapy Antiviral Research 85 2010 25 33
5. L. Menéndez-Arias Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments Antiviral Research 98 2013 93 120
6. P.M. Grant, and A.R. Zolpa Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance Current Opinion in Investigational Drugs 11 2010 901 910
7. K.J. Cortez, and F. Maldarelli Clinical management of HIV drug resistance Viruses 3 2011 347 378
8. T. Howkins Understanding and managing the adverse effects of antiretroviral therapy Antiviral Research 85 2010 201 209
9. V. Famiglini, A. Coluccia, A. Brancale, G. La Regina, and R. Silvestri Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors Future Medicinal Chemistry 18 2013 2141 2156
10. R. Silvestri, G. De Martino, G. La Regina, M. Artico, S. Massa, L. Vargiu, M. Mura, A.G. Loi, T. Marceddu, and P. La Colla Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies Journal of Medicinal Chemistry 46 2003 2482 2493
11. R. Silvestri, M. Artico, G. De Martino, G. La Regina, R. Loddo, M. La Colla, and P. La Colla Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild-type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations Journal of Medicinal Chemistry 47 2004 3892 3896
12. F. Piscitelli, A. Coluccia, A. Brancale, G. La Regina, A. Sansone, C. Giordano, J. Balzarini, G. Maga, S. Zanoli, A. Samuele, R. Cirilli, R.F. La Torre, A. Lavecchia, E. Novellino, and R. Silvestri Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and Coxsackie B4 virus Journal of Medicinal Chemistry 52 2009 1922 1934
13. R. Ragno, M. Artico, G. De Martino, G. La Regina, A. Coluccia, A. Di Pasquali, and R. Silvestri Docking and 3-D QSAR studies on indolyl aryl sulfones (IASs). Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl) carboxyamide and N-(2-hydroxyethyl)-carboxyhydrazide derivatives Journal of Medicinal Chemistry 48 2005 213 223
14. R. Ragno, A. Coluccia, G. La Regina, G. De Martino, F. Piscitelli, A. Lavecchia, E. Novellino, A. Bergamini, C. Ciaprini, A. Sinistro, G. Maga, E. Crespan, M. Artico, and R. Silvestri Design, molecular modeling, synthesis and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide Journal of Medicinal Chemistry 49 2006 3172 3184
15. G. La Regina, A. Coluccia, and R. Silvestri Looking for an active conformation of the future HIV-1 non-nucleoside reverse transcriptase inhibitors Antiviral Chemistry and Chemotherapy 20 2010 231 237
16. P. Chong, P. Sebahar, M. Youngman, D. Garrido, H. Zhang, E.L. Stewart, R.T. Nolte, L. Wang, R.G. Ferris, M. Edelstein, K. Weaver, A. Mathis, and A. Peat Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase Journal of Medicinal Chemistry 55 2012 10601 10609
17. G. La Regina, A. Coluccia, A. Brancale, F. Piscitelli, V. Gatti, G. Maga, A. Samuele, C. Pannecouque, D. Schols, J. Balzarini, E. Novellino, and R. Silvestri Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors. New cyclic substituents at the indole-2-carboxamide Journal of Medicinal Chemistry 54 2011 1587 1598
18. J.W. Corbett, and J.D. Rodgers Discovery of second generation of quinazoline non-nucleoside reverse transcriptase inhibitors of HIV-1 Progress in Medicinal Chemistry 40 2002 63 105
19. Z. Zhao, S.E. Wolkenberg, M. Lu, V. Munshi, G. Moyer, M. Feng, A.V. Carella, L.T. Ecto, L.J. Gabryelski, M.T. Lai, S.G. Prasad, Y. Yan, G.B. McGaughey, M.D. Miller, C.W. Lindsley, G.D. Hartman, J.P. Vacca, and T.M. Williams Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) Bioorganic & Medicinal Chemistry Letters 18 2008 554 559
20. M. Geitmann, T. Unge, and H.U. Danielson Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance Journal of Medicinal Chemistry 49 2006 2375 2387
21. E. Gonzalez-Ortega, E. Ballana, R. Badia, B. Clotet, and J.A. Estè Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1 Antiviral Research 92 2011 479 483
22. A.N. Van Nhien, C. Tomassi, C. Len, J.L. Marco-Contelles, J. Balzarini, C. Pannecouque, E. De Clercq, and D. Postel First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication Journal of Medicinal Chemistry 48 2005 4276 4284
23. G. Maga, M. Amacker, N. Ruel, U. Hubsher, and S. Spadari Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or stearic barriers are induced by different single amino acid substitutions Journal of Molecular Biology 274 1997 738 747
24. J. Ren, J. Milton, K.L. Weaver, S.A. Short, D.I. Stuart, and D.K. Stammers Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase Structure Folding and Design 8 2000 1089 1094
25. Molecular Operating Environment (MOE). Chemical Computing Group, Inc. Montreal, Quebec, Canada. www.chemcomp.com.
26. O. Korb, T. Stutzle, and T.E. Exner PLANTS: application of ant colony optimization to structure-based drug design M. Dorigo, L.M. Gambardella, M. Birattari, A. Martinoli, R. Poli, T. Stutzle, In Ant Colony Optimization and Swarm Intelligence, Proceedings of the 5th International Workshop, ANTS Lecture Notes in Computer Science, Series 4150 2006 Springer Berlin 247 258
27. PyMOL version 1.2r1; DeLano Scientific LLC: San Carlos, CA http://www.pymol.org/.